Walgreens Boots Alliance, Inc. USDC – Northern District of Illinois January 31, 2025 CLASS PERIOD: april 2, 2020 – january 16, 2025LEAD PLAINTIFF DEADLINE: march 31, 2025 Please complete the form below to contact Kaplan Fox regarding the Walgreens Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comPamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Walgreens Boots Alliance, Inc. (WBA) – Deadline is March 31, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) on behalf of investors that purchased or otherwise acquired Walgreens securities between April 2, 2020 and January 16, 2025 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Walgreens and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 31, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. After markets closed, on January 17, 2025, the United States Department of Justice (“DOJ”) issued a press release entitled “Justice Department Files Nationwide Lawsuit Alleging Walgreens Knowingly Filled Millions of Prescriptions that Lacked a Legitimate Medical Purpose.” The announcement stated that “[t]he government’s complaint alleges that, from approximately August 2012 through the present, Walgreens knowingly filled millions of prescriptions for controlled substances that lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice.” The DOJ also states the Company “dispensed millions of unlawful prescriptions in violation of the Controlled Substances Act” as well as violations of the False Claims Act for seeking “reimbursement for many of these prescriptions from various federal health care programs.” On January 21, 2025, the first trading day following this news, the price of Walgreens stock fell $1.15 per share, over 9%, to close at $11.37. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; (ii) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny civil liability, and reputational harm; and (iii) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Polestar Automotive Holding UK PLC See the Case Walgreens Boots Alliance, Inc. See the Case Crocs, Inc. See the Case Electronic Arts Inc. See the Case FTAI Aviation Ltd. See the Case Innovative Industrial Properties, Inc. See the Case AstraZeneca PLC See the Case TransMedics Group, Inc. See the Case Nextracker Inc. See the Case Revance Therapeutics, Inc. See the Case Carvana Co. See the Case MGP Ingredients, Inc. See the Case
